The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2020 | Treating relapsed/refractory CLL with venetoclax
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL). Chemo-immunotherapy is no longer being used routinely. Instead, physicians choose between continuous treatment with BTK inhibitors or time limited treatment with venetoclax plus rituximab. These treatment decisions have to be made on an individual basis. There are also questions on the use of frontline therapies, such as when to repeat treatment with venetoclax. This interview took place during the European Research Initiative on CLL (ERIC) International Virtual Meeting 2020.
